Video

November 12, 2021

LUGPA 2021: Health policy challenges for urology practices

“The biggest challenge we have is looming cuts from Medicare and reimbursement,” says Gary Kirsh, MD.

At the 2021 LUGPA Annual Meeting, Gary Kirsh, MD, chair, LUGPA Political Affairs Committee and president, The Urology Group, discussed health policy challenges facing urology practices.

Related Content

Welcome to Fabulous Las Vegas Neon Sign | Image Credit: © somchaij - stock.adobe.com

April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke

We preview several noteworthy P2 presentations in the urologic oncology space.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor

“Among active surveillance patients, 82% are metastases-free, and 60% were metastases-free and had an intact, unradiated bladder,” said Pooja Ghatalia, MD.

May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com

February 17th 2025

Casdatifan is linked with promising safety, efficacy in clear cell RCC

Benjamin P. Saylor

“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.

Urinary bladder cancer | Image Credit: © Matthieu - stock.adobe.com

February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.

Related Content

April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke

We preview several noteworthy P2 presentations in the urologic oncology space.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor

“Among active surveillance patients, 82% are metastases-free, and 60% were metastases-free and had an intact, unradiated bladder,” said Pooja Ghatalia, MD.

May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

February 17th 2025

Casdatifan is linked with promising safety, efficacy in clear cell RCC

Benjamin P. Saylor

“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.

February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.